Literature DB >> 31509650

Health-Related Quality of Life and Cognitive Functioning in Pediatric Liver Transplant Recipients.

Daniella Ohnemus1, Katie Neighbors2, Karen Rychlik3, Robert S Venick4, John C Bucuvalas5, Shikha S Sundaram6, Vicky L Ng7, Walter S Andrews8, Yumi Turmelle9, George V Mazariegos10, Lisa G Sorensen11, Estella M Alonso2.   

Abstract

The goal of this work was to examine the change in health-related quality of life (HRQOL) and cognitive functioning from early childhood to adolescence in pediatric liver transplantation (LT) recipients. Patients were recruited from 8 North American centers through the Studies of Pediatric Liver Transplantation consortium. A total of 79 participants, ages 11-18 years, previously tested at age 5-6 years in the Functional Outcomes Group study were identified as surviving most recent LT by 2 years and in stable medical follow-up. The Pediatric Quality of Life 4.0 Generic Core Scale, Pediatric Quality of Life Cognitive Function Scale, and PROMIS Pediatric Cognitive Function tool were distributed to families electronically. Data were analyzed using repeated measures and paired t tests. Predictive variables were analyzed using univariate regression analysis. Of the 69 families contacted, 65 (94.2%) parents and 61 (88.4%) children completed surveys. Median age of participants was 16.1 years (range, 12.9-18.0 years), 55.4% were female, 33.8% were nonwhite, and 84.0% of primary caregivers had received at least some college education. Median age at LT was 1.1 years (range, 0.1-4.8 years). The majority of participants (86.2%) were not hospitalized in the last year. According to parents, adolescents had worse HRQOL and cognitive functioning compared with healthy children in all domains. Adolescents reported HRQOL similar to healthy children in all domains except psychosocial, school, and cognitive functioning (P = 0.02; P < 0.001; P = 0.04). Participants showed no improvement in HRQOL or cognitive functioning over time. For cognitive and school functioning, 60.0% and 50.8% of parents reported "poor" functioning, respectively (>1 standard deviation below the healthy mean). Deficits in HRQOL seem to persist in adolescence. Over half of adolescent LT recipients appear to be at risk for poor school and cognitive functioning, likely reflecting attention and executive function deficits.
Copyright © 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Year:  2019        PMID: 31509650     DOI: 10.1002/lt.25634

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  5 in total

1.  Posttraumatic stress and medication adherence in pediatric transplant recipients.

Authors:  Sarah Duncan-Park; Lara Danziger-Isakov; Brian Armstrong; Nikki Williams; Jonah Odim; Eyal Shemesh; Stuart Sweet; Rachel Annunziato
Journal:  Am J Transplant       Date:  2021-12-20       Impact factor: 8.086

2.  Health-Related Quality of Life 10 Years after Liver Transplantation: A Longitudinal Retrospective Review.

Authors:  Amber Hager; Diana Mager; Cheri Robert; David Nicholas; Susan Gilmour
Journal:  Diagnostics (Basel)       Date:  2021-01-12

3.  Dexmedetomidine Ameliorates Hippocampus Injury and Cognitive Dysfunction Induced by Hepatic Ischemia/Reperfusion by Activating SIRT3-Mediated Mitophagy and Inhibiting Activation of the NLRP3 Inflammasome in Young Rats.

Authors:  Wenli Yu; Jingshu Lyu; Lili Jia; Mingwei Sheng; Hongli Yu; Hongyin Du
Journal:  Oxid Med Cell Longev       Date:  2020-11-20       Impact factor: 6.543

4.  French-language adaptation of the 16D and 17D Quality of Life measures and score description in two Canadian pediatric samples.

Authors:  Émélie Rondeau; Leandra Desjardins; Caroline Laverdière; Daniel Sinnett; Élie Haddad; Serge Sultan
Journal:  Health Psychol Behav Med       Date:  2021-07-06

5.  Longitudinal osmotic and neurometabolic changes in young rats with chronic cholestatic liver disease.

Authors:  Veronika Rackayova; Olivier Braissant; Anne-Laure Rougemont; Cristina Cudalbu; Valérie A McLin
Journal:  Sci Rep       Date:  2020-05-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.